TLR7 and cancer: This leads to the release and translocation ofactivated NF-κB or AP-1 to the nucleus, where the expressionof pro-inflammatory cytokines and type I interferons is induced.5−7 It was shown previously that upregulated or downregulated TLR7 signalingis involved in the development and progression of numerous diseases,including chronic inflammatory and infectious diseases, autoimmunediseases, and cancer.8−10 However, the use of TLR7 agonists in the treatmentof these diseases is still in the research phase, so further clinicalstudies are needed to fully understand their role and efficacy.